Albendazole versus metronidazole in the treatment of adult giardiasis: a randomized, double-blind, clinical trial.

Research paper by Roberto R Cañete, Pablo P Rodríguez, Lumey L Mesa, Katia K Brito, Ada A Prior, Dirce D Guilhem, M R C G MR Novaes

Indexed on: 26 Nov '11Published on: 26 Nov '11Published in: Current medical research and opinion


Albendazole (ABZ) is a benzimidazole carbamate compound currently in use for human medical practice against enterobiasis and soil-transmitted helminthiasis (STH); However, its spectrum of activity is broad and goes beyond these infections.This study compares the efficacy and safety of ABZ versus metronidazole (MTZ) in human giardiasis.A randomized, double-blind, clinical trial was carried out at the Centre of Hygiene, Epidemiology and Microbiology in Matanzas City, Cuba. Adult patients with confirmed symptomatic G. duodenalis mono-infection were randomly assigned to receive either ABZ [400 mg daily (n = 75)] or MTZ [250 mg t.i.d. (n = 75)], both for 5 days. Follow-up fecal samples were obtained at 3, 5, 7 days after treatment end.The efficacy was similar for both treatment groups: ABZ (82.6%) and MTZ (85.3%); p > 0.05. Side-effects including bitter taste, headache, vomiting and dizziness were significantly higher in the MTZ group. Abdominal pain was significantly higher in ABZ group.ABZ was found as effective as MTZ in the treatment of G. duodenalis infections in adult patients from Cuba and could be a useful drug in areas where co-infection with STH infections is common.